Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX), citing the company’s BNT327, an immuno-oncology asset in clinical ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory syncytial ...

Arbutus Biopharma Corp (ABUS) showcases significant progress in hepatitis B treatment and maintains a robust cash runway into ...

Good day. And thank you for standing by Welcome to the Arbutus BioPharma 2024 3rd quarter, financial results and corporate update. (Operator Instructions) I would now like to hand the conference over ...

Last week, you might have seen that BioNTech SE ( NASDAQ:BNTX ) released its quarterly result to the market. The ...

Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...

Q3 2024 Earnings Call Transcript November 4, 2024 Operator: Welcome to BioNTech’s Third Quarter 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor ...

BioNTech SE (BNTX) has released an update. BioNTech SE reported a strong third quarter in 2024, with revenues reaching €1.2 ...

BioNTech SE (BNTX) has released an update. BioNTech SE’s quarterly report for the period ending September 30, 2024, reveals a ...

Third Quarter 2024 Results Key Financial Results Revenue: €1.24b (up 39% from 3Q 2023).

Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz Director, Investor Relations. Please go ahead.